Sign in or create an account to add this stock to your watchlist.
About NovoCure (NASDAQ:NVCR)
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
Debt
Debt-to-Equity Ratio1.41
Current Ratio6.32
Quick Ratio5.87
Price-To-Earnings
Trailing P/E Ratio-43.36
Forward P/E Ratio-50.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.03 million
Price / Sales15.55
Cash FlowN/A
Price / CashN/A
Book Value$1.17 per share
Price / Book25.94
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-33.12%
Return on Equity-56.70%
Return on Assets-23.65%
Miscellaneous
Employees495
Outstanding Shares90,700,000
NovoCure (NASDAQ:NVCR) Frequently Asked Questions
What is NovoCure's stock symbol?
NovoCure trades on the NASDAQ under the ticker symbol "NVCR."
How were NovoCure's earnings last quarter?
NovoCure (NASDAQ:NVCR) posted its quarterly earnings data on Thursday, April, 26th. The medical equipment provider reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.10. The medical equipment provider had revenue of $52.13 million for the quarter, compared to analysts' expectations of $57.13 million. NovoCure had a negative return on equity of 56.70% and a negative net margin of 33.12%. View NovoCure's Earnings History.
When is NovoCure's next earnings date?
What price target have analysts set for NVCR?
4 brokers have issued 12 month target prices for NovoCure's stock. Their predictions range from $19.00 to $33.00. On average, they anticipate NovoCure's stock price to reach $28.00 in the next year. View Analyst Ratings for NovoCure.
What are Wall Street analysts saying about NovoCure stock?
Here are some recent quotes from research analysts about NovoCure stock:
- 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (5/1/2018)
- 2. Mizuho analysts commented, "We now anticipate a potential FDA approval for the mesothelioma indication before year-end 2018 given the company’s filing under Humanitarian Device Exemption. We updated our model to reflect revenues from mesothelioma in the coming years and raise our PT to $32." (4/18/2018)
Who are some of NovoCure's key competitors?
Some companies that are related to NovoCure include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS) and Luminex (LMNX).
Who are NovoCure's key executives?
NovoCure's management team includes the folowing people:
- Mr. William F. Doyle, Exec. Chairman (Age 56)
- Mr. Asaf Danziger, CEO & Director (Age 52)
- Mr. Kinyip Gabriel Leung, Vice Chairman & Chairman of the Global Commercialization Team (Age 56)
- Prof. Yoram Palti, Founder, CTO & Director (Age 80)
- Mr. Wilhelmus C. M. Groenhuysen, CFO & Principal Accounting Officer (Age 60)
Has NovoCure been receiving favorable news coverage?
Media stories about NVCR stock have trended positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovoCure earned a coverage optimism score of 0.31 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 46.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are NovoCure's major shareholders?
NovoCure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.16%), Baillie Gifford & Co. (3.03%), Farallon Capital Management LLC (2.04%), StepStone Group LP (1.51%), Tamarack Advisers LP (1.23%) and Frontier Capital Management Co. LLC (1.22%). Company insiders that own NovoCure stock include Asaf Danziger, Eilon D Kirson, Gabriel Leung, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for NovoCure.
Which major investors are selling NovoCure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including StepStone Group LP, Millennium Management LLC, Cortina Asset Management LLC, Westfield Capital Management Co. LP, JPMorgan Chase & Co., A.R.T. Advisors LLC, Pier Capital LLC and BlackRock Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for NovoCure.
Which major investors are buying NovoCure stock?
NVCR stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., PointState Capital LP, Loomis Sayles & Co. L P, Farallon Capital Management LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Nuveen Asset Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for NovoCure.
How do I buy shares of NovoCure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovoCure's stock price today?
One share of NVCR stock can currently be purchased for approximately $30.35.
How big of a company is NovoCure?
NovoCure has a market capitalization of $2.77 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. NovoCure employs 495 workers across the globe.
How can I contact NovoCure?
NovoCure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for NovoCure (NVCR)
MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
NovoCure (NASDAQ:NVCR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for NovoCure in the last 12 months. Their average twelve-month price target is $28.00, suggesting that the stock has a possible downside of 7.74%. The high price target for NVCR is $33.00 and the low price target for NVCR is $19.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.86 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.00 | $22.60 | $21.2857 | $20.8571 |
| Price Target Upside: | 7.74% downside | 16.30% downside | 6.56% upside | 10.36% upside |
NovoCure (NASDAQ:NVCR) Consensus Price Target History
NovoCure (NASDAQ:NVCR) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
NovoCure (NASDAQ:NVCR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NovoCure (NASDAQ NVCR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 48.14%
NovoCure (NASDAQ NVCR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Gabriel Leung | Director | Sell | 80,000 | $28.83 | $2,306,400.00 | |  |
| 5/14/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 30,470 | $30.04 | $915,318.80 | 201,898 | |
| 5/11/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 9,393 | $30.01 | $281,883.93 | 201,898 | |
| 5/1/2018 | Michael J Ambrogi | COO | Sell | 60,000 | $27.40 | $1,644,000.00 | | |
| 5/1/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 30,470 | $27.58 | $840,362.60 | | |
| 4/26/2018 | Michael J Ambrogi | COO | Sell | 20,000 | $26.01 | $520,200.00 | 166,558 | |
| 4/26/2018 | Yoram Palti | Insider | Sell | 20,966 | $26.09 | $547,002.94 | | |
| 4/24/2018 | Yoram Palti | Insider | Sell | 35,600 | $25.06 | $892,136.00 | | |
| 4/20/2018 | Yoram Palti | CTO | Sell | 19,362 | $25.06 | $485,211.72 | | |
| 4/18/2018 | Michael J Ambrogi | COO | Sell | 40,000 | $23.03 | $921,200.00 | 166,558 | |
| 4/18/2018 | Yoram Palti | Insider | Sell | 44,072 | $23.65 | $1,042,302.80 | 116,451 | |
| 4/3/2018 | Yoram Palti | Insider | Sell | 60,000 | $20.32 | $1,219,200.00 | | |
| 3/29/2018 | Yoram Palti | CTO | Sell | 30,000 | $21.67 | $650,100.00 | | |
| 2/23/2018 | Michael J Ambrogi | COO | Sell | 8,458 | $19.83 | $167,722.14 | 105,288 | |
| 2/23/2018 | Todd Christopher Longsworth | General Counsel | Sell | 6,591 | $19.83 | $130,699.53 | 26,665 | |
| 2/23/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 13,351 | $19.83 | $264,750.33 | 252,412 | |
| 1/29/2018 | Asaf Danziger | CEO | Sell | 13,974 | $24.02 | $335,655.48 | 356,790 | |
| 1/29/2018 | Todd Christopher Longsworth | General Counsel | Sell | 11,630 | $24.00 | $279,120.00 | 16,628 | |
| 1/24/2018 | Asaf Danziger | CEO | Sell | 20,848 | $22.10 | $460,740.80 | 387,820 | |
| 1/16/2018 | Asaf Danziger | CEO | Sell | 14,900 | $22.20 | $330,780.00 | 398,068 | |
| 1/12/2018 | Asaf Danziger | CEO | Sell | 336,420 | $22.33 | $7,512,258.60 | 435,863 | |
| 1/11/2018 | Eilon D Kirson | Insider | Sell | 25,320 | $22.00 | $557,040.00 | 3,181 | |
| 1/9/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 31,132 | $21.02 | $654,394.64 | 240,210 | |
| 1/4/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 28,868 | $21.03 | $607,094.04 | 268,568 | |
| 11/13/2017 | Yoram Palti | Insider | Sell | 30,000 | $17.13 | $513,900.00 | | |
| 11/9/2017 | Yoram Palti | CTO | Sell | 30,000 | $18.25 | $547,500.00 | | |
| 11/7/2017 | Yoram Palti | Insider | Sell | 60,000 | $21.06 | $1,263,600.00 | | |
| 11/6/2017 | Asaf Danziger | CEO | Sell | 6,919 | $22.00 | $152,218.00 | | |
| 11/3/2017 | Asaf Danziger | CEO | Sell | 2,300 | $22.00 | $50,600.00 | 756,024 | |
| 11/3/2017 | Eilon D Kirson | Insider | Sell | 3,400 | $22.00 | $74,800.00 | 40,701 | |
| 11/3/2017 | Michael J Ambrogi | COO | Sell | 1,200 | $22.00 | $26,400.00 | 24,987 | |
| 11/2/2017 | Yoram Palti | CTO | Sell | 30,000 | $21.78 | $653,400.00 | | |
| 11/1/2017 | Asaf Danziger | CEO | Sell | 15,866 | $22.01 | $349,210.66 | 774,040 | |
| 11/1/2017 | Eilon D Kirson | Insider | Sell | 22,269 | $22.01 | $490,140.69 | 63,120 | |
| 11/1/2017 | Michael J Ambrogi | COO | Sell | 24,327 | $22.01 | $535,437.27 | 49,514 | |
| 9/25/2017 | Asaf Danziger | CEO | Sell | 900 | $22.05 | $19,845.00 | 774,190 | |
| 9/14/2017 | Asaf Danziger | CEO | Sell | 37,272 | $22.01 | $820,356.72 | 776,862 | |
| 9/13/2017 | Asaf Danziger | CEO | Sell | 35,500 | $22.01 | $781,355.00 | 776,862 | |
| 7/11/2017 | Asaf Danziger | CEO | Sell | 7,383 | $19.95 | $147,290.85 | 462,765 | |
| 7/10/2017 | Asaf Danziger | CEO | Sell | 274,359 | $18.07 | $4,957,667.13 | 668,865 | |
| 7/6/2017 | Asaf Danziger | CEO | Sell | 160,138 | $18.14 | $2,904,903.32 | 899,462 | |
| 7/5/2017 | Asaf Danziger | CEO | Sell | 155,088 | $18.14 | $2,813,296.32 | 899,462 | |
| 6/26/2017 | Pomona Capital Vii Fund Invest | Major Shareholder | Sell | 1,072,532 | $17.35 | $18,608,430.20 | | |
| 6/21/2017 | Eilon D Kirson | Insider | Sell | 66,361 | $16.78 | $1,113,537.58 | 222,722 | |
| 6/19/2017 | Asaf Danziger | CEO | Sell | 124,720 | $15.51 | $1,934,407.20 | 896,917 | |
| 6/19/2017 | Eilon D Kirson | Insider | Sell | 15,000 | $15.06 | $225,900.00 | 289,083 | |
| 6/16/2017 | Asaf Danziger | CEO | Sell | 42,457 | $15.15 | $643,223.55 | 1,030,849 | |
| 6/14/2017 | Asaf Danziger | CEO | Sell | 94,102 | $15.22 | $1,432,232.44 | 1,069,496 | |
| 6/12/2017 | Asaf Danziger | CEO | Sell | 180,601 | $15.13 | $2,732,493.13 | 1,163,296 | |
| 6/12/2017 | Eilon D Kirson | Insider | Sell | 20,956 | $15.03 | $314,968.68 | 319,083 | |
| 6/5/2017 | Yoram Palti | Insider | Sell | 3,825 | $13.82 | $52,861.50 | | |
| 6/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $13.27 | $106,160.00 | 7,825 | |
| 5/31/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.49 | $99,920.00 | 15,825 | |
| 5/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.88 | $103,040.00 | 23,825 | |
| 5/24/2017 | Yoram Palti | Insider | Sell | 4,000 | $13.15 | $52,600.00 | 29,256 | |
| 5/23/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.73 | $93,840.00 | 35,825 | |
| 5/19/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.39 | $91,120.00 | 43,825 | |
| 5/17/2017 | Yoram Palti | Insider | Sell | 4,000 | $11.47 | $45,880.00 | 47,825 | |
| 5/16/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.05 | $96,400.00 | 55,825 | |
| 5/12/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.79 | $94,320.00 | 63,825 | |
| 5/10/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.29 | $98,320.00 | 71,825 | |
| 5/8/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.82 | $94,560.00 | 79,825 | |
| 5/4/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.42 | $91,360.00 | 87,825 | |
| 5/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.64 | $93,120.00 | 95,825 | |
| 4/28/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.25 | $90,000.00 | 103,825 | |
| 4/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $10.78 | $86,240.00 | 111,825 | |
| 4/24/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.26 | $90,080.00 | 119,825 | |
| 4/20/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.24 | $89,920.00 | 127,825 | |
| 4/18/2017 | Yoram Palti | Insider | Sell | 16,000 | $10.64 | $170,240.00 | 143,825 | |
| 4/17/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.77 | $43,080.00 | 143,825 | |
| 4/13/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.43 | $41,720.00 | 143,825 | |
| 4/12/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.72 | $42,880.00 | 143,825 | |
| 3/14/2017 | Gert L Perlhagen | Director | Buy | 125,000 | $6.93 | $866,250.00 | 6,125,000 | |
| 12/22/2016 | Michael J Ambrogi | COO | Sell | 27,500 | $8.27 | $227,425.00 | 139,084 | |
| 12/20/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.62 | $172,400.00 | 179,084 | |
| 12/19/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.76 | $175,200.00 | 179,084 | |
| 12/16/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.93 | $357,200.00 | 219,084 | |
| 12/14/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.97 | $358,800.00 | 259,084 | |
| 12/12/2016 | Michael J Ambrogi | COO | Sell | 15,000 | $9.01 | $135,150.00 | 289,084 | |
| 12/8/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.30 | $83,000.00 | 299,084 | |
| 12/6/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.24 | $82,400.00 | 309,084 | |
| 8/5/2016 | Gert L Perlhagen | Director | Sell | 676,576 | $1.85 | $1,251,665.60 | 676,576 | |
| 6/8/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $12.24 | $244,800.00 | 324,084 | |
| 3/3/2016 | Asaf Danziger | CEO | Buy | 10,000 | $15.00 | $150,000.00 | 933,557 | |
| 3/3/2016 | Robert J Mylod Jr | Director | Buy | 20,000 | $15.78 | $315,600.00 | 148,114 | |
(Data available from 1/1/2013 forward)
NovoCure (NASDAQ NVCR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NovoCure (NVCR) Expected to Post Quarterly Sales of $58.84 Million
www.americanbankingnews.com - May 22 at 5:02 AM |
| -$0.15 EPS Expected for NovoCure (NVCR) This Quarter
www.americanbankingnews.com - May 20 at 1:16 AM |
| BidaskClub Downgrades NovoCure (NVCR) to Buy
www.americanbankingnews.com - May 19 at 11:02 AM |
| Gabriel Leung Sells 80,000 Shares of NovoCure (NVCR) Stock
www.americanbankingnews.com - May 17 at 7:34 PM |
 | 3 Young Biotechs Positioned To Upend Medicine
seekingalpha.com - May 17 at 7:09 PM |
| NovoCure (NVCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 17 at 10:38 AM |
| Insider Selling: NovoCure (NVCR) CFO Sells $281,883.93 in Stock
www.americanbankingnews.com - May 15 at 7:52 PM |
| Insider Selling: NovoCure (NVCR) CFO Sells 30,470 Shares of Stock
www.americanbankingnews.com - May 15 at 7:36 PM |
| NovoCure (NVCR) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - May 12 at 7:35 AM |
| $59.02 Million in Sales Expected for NovoCure (NVCR) This Quarter
www.americanbankingnews.com - May 4 at 3:02 AM |
| NovoCure (NVCR) CFO Sells $840,362.60 in Stock
www.americanbankingnews.com - May 3 at 7:52 PM |
| NovoCure (NVCR) COO Sells $1,644,000.00 in Stock
www.americanbankingnews.com - May 3 at 7:33 PM |
| NovoCure (NVCR) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM |
| NovoCure (NVCR) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 2 at 1:12 PM |
| Zacks Investment Research Lowers NovoCure (NVCR) to Hold
www.americanbankingnews.com - May 1 at 6:36 AM |
| Michael J. Ambrogi Sells 20,000 Shares of NovoCure (NVCR) Stock
www.americanbankingnews.com - April 30 at 7:46 PM |
| Insider Selling: NovoCure (NVCR) Insider Sells 20,966 Shares of Stock
www.americanbankingnews.com - April 30 at 7:28 PM |
| NovoCure: 2018 Off To A Strong Start For Optune
seekingalpha.com - April 30 at 5:21 PM |
| Novocure Hints To Additional Stellar Data And Validation
seekingalpha.com - April 30 at 8:10 AM |
 | Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT
finance.yahoo.com - April 27 at 5:21 PM |
| Wedbush Boosts NovoCure (NVCR) Price Target to $33.00
www.americanbankingnews.com - April 27 at 2:30 PM |
 | NovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche Bank
www.streetinsider.com - April 27 at 8:14 AM |
| Investors Buy High Volume of NovoCure Put Options (NVCR)
www.americanbankingnews.com - April 27 at 7:44 AM |
| Stock Traders Purchase Large Volume of Call Options on NovoCure (NVCR)
www.americanbankingnews.com - April 27 at 7:44 AM |
| NovoCure (NVCR) Announces Earnings Results
www.americanbankingnews.com - April 26 at 7:30 PM |
| Novocure (NVCR) Misses Q1 EPS by 10c, Miss on Revenues
www.streetinsider.com - April 26 at 5:23 PM |
| NovoCure: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 5:23 PM |
| This Explains Why NovoCure Is Surging Today
finance.yahoo.com - April 26 at 5:23 PM |
| Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - April 26 at 8:07 AM |
| Zacks Investment Research Upgrades NovoCure (NVCR) to "Buy"
www.americanbankingnews.com - April 26 at 6:10 AM |
| NovoCure (NVCR) Insider Yoram Palti Sells 35,600 Shares
www.americanbankingnews.com - April 25 at 7:10 PM |
| NovoCure (NVCR) Shares March Higher, Can It Continue
finance.yahoo.com - April 25 at 5:37 PM |
| NovoCure (NVCR) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - April 24 at 9:58 AM |
| NovoCure (NVCR) CTO Sells $485,211.72 in Stock
www.americanbankingnews.com - April 23 at 4:24 PM |
| NovoCure (NVCR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 7:48 AM |
 | BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
www.reuters.com - April 20 at 5:30 PM |
| NovoCure (NVCR) Insider Sells $1,042,302.80 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| NovoCure (NVCR) COO Sells $921,200.00 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| NovoCure (NVCR) Upgraded at Deutsche Bank
www.americanbankingnews.com - April 19 at 10:01 AM |
 | Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...
globenewswire.com - April 19 at 8:07 AM |
| Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma
finance.yahoo.com - April 19 at 8:07 AM |
| Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 19 at 8:07 AM |
| NovoCure (NVCR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:34 AM |
| NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
finance.yahoo.com - April 18 at 5:53 PM |
| NovoCure (NVCR) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 18 at 9:00 AM |
| BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma
www.reuters.com - April 17 at 6:06 PM |
| NovoCure (NVCR) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 1:54 PM |
 | What's Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage Medical
www.prnewswire.com - April 17 at 8:16 AM |
| Novocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
www.streetinsider.com - April 17 at 8:16 AM |
| Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
finance.yahoo.com - April 17 at 8:16 AM |
NovoCure (NASDAQ:NVCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NovoCure (NASDAQ:NVCR) Income Statement, Balance Sheet and Cash Flow Statement
NovoCure (NASDAQ NVCR) Stock Chart for Sunday, May, 27, 2018
Loading chart…
